Korro Bio Inc. unveils corporate presentation on RNA editing therapies for rare and prevalent diseases
Reuters
Nov 13, 2025
<a href="https://laohu8.com/S/KRRO">Korro Bio</a> Inc. unveils corporate presentation on RNA editing therapies for rare and prevalent diseases
Korro Bio Inc. provided an update on its RNA editing pipeline, highlighting interim data from the Phase 1/2a REWRITE study of KRRO-110 in patients with alpha-1 antitrypsin deficiency (AATD). The study showed generation of functional M-AAT protein and a tolerable safety profile consistent with lipid nanoparticle infusion effects. However, projected levels of functional protein were not reached after a single administration, and differences in pharmacokinetics were observed between healthy volunteers and AATD patients. The company announced a strategic shift to GalNAc-conjugated delivery for AATD with a development candidate expected in the first half of 2026. Korro Bio also nominated KRRO-121, a GalNAc-conjugated construct targeting hyperammonemia and broader urea cycle disorders, with regulatory filing planned for the second half of 2026. The company reported cash, cash equivalents, and marketable securities totaling $102.5 million as of September 30, 2025, supporting operations into the second half of 2027. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Korro Bio Inc. published the original content used to generate this news brief on November 12, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.